Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 7/20 | 0.54 |
| ▸ | MAP1LC3B | Q9GZQ8 | 3/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | PDE6D | O43924 | 4/20 | 0.45 |
| ▸ | NAMPT | P43490 | 7/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5524193 | 1.00 | KIF11 (0.54) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL5533059 | 0.91 | KIF11 (0.53) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL5723804 | 0.90 | KIF11 (0.61) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL5723915 | 0.90 | KIF11 (0.61) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL5524041 | 0.90 | KIF11 (0.54) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL5526280 | 0.89 | KIF11 (0.54) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL14544724 | 0.85 | KIF11 (0.43) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL14393429 | 0.85 | KIF11 (0.43) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL5521482 | 0.85 | KIF11 (0.59) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL5520334 | 0.85 | KIF11 (0.68) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254870-A1 | Compounds, compositions and methods | CYTOKINETICS, INC. | 2007-11-01 | — | — | US | disclosed |
| US-7208487-B2 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED (US) | 2007-04-24 | — | — | US | disclosed |
| US-20060052360-A1 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052360-A1 | Compounds, compositions and methods | ALPP, PCNA, MKI67 | KIF11 824/4885MAP1LC3B 1516/4885CYP3A4 4658/4885 |
| US-20070254870-A1 | Compounds, compositions and methods | ALPP, PCNA, MKI67 | KIF11 824/4885MAP1LC3B 1516/4885CYP3A4 4658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.